Insulin Dosing for Hyperglycemia in the Emergency Department
Direct Recommendation
For adult patients presenting to the emergency department with non-ketotic hyperglycemia (blood glucose 200-400 mg/dL), use subcutaneous rapid-acting insulin (insulin aspart) every 2 hours at a dose of 0.1 units/kg until blood glucose falls below 200 mg/dL, rather than sliding scale regular insulin alone. 1, 2
Treatment Protocol
Initial Assessment and Dosing
- Start subcutaneous rapid-acting insulin when blood glucose is ≥200 mg/dL in patients with known diabetes
- Initial dose: 0.1 units/kg of rapid-acting insulin (insulin aspart) 3
- Repeat dosing: Every 2 hours until blood glucose <200 mg/dL 1, 2
- Monitor: Point-of-care blood glucose every 2 hours 1
Insulin Type Selection
Both regular insulin and rapid-acting insulin (aspart) demonstrate similar efficacy in the ED setting, with no significant difference in blood glucose reduction rates (41.5 mg/dL/h vs 47 mg/dL/h, p=0.36) 3. However, rapid-acting insulin protocols have been more extensively studied and validated in ED hyperglycemia management 1, 2.
Route of Administration
Subcutaneous insulin is preferred over intravenous insulin for non-emergent hyperglycemia in the ED:
- IV insulin doses >5 units provide only modest glucose reduction (37.4 mg/dL) with no improvement in ED length of stay 4
- IV insulin carries a 7.9% risk of hypokalemia 4
- Subcutaneous protocols achieve mean glucose reduction from 333 mg/dL to 158 mg/dL safely 1
Critical Pitfalls to Avoid
Do not use sliding scale insulin alone in patients with established diabetes. This approach is explicitly discouraged in guidelines and associated with poor glycemic control 5. Sliding scale insulin only treats hyperglycemia after it occurs rather than preventing it.
Avoid aggressive IV insulin protocols for non-emergent hyperglycemia (200-400 mg/dL range). These are reserved for critically ill patients with persistent hyperglycemia ≥180 mg/dL 6. The 2024 Society of Critical Care Medicine guidelines specify that insulin therapy should be triggered at ≥180 mg/dL in critically ill patients, but your ED population with 200-400 mg/dL is not critically ill by definition.
Expected Outcomes
- Glucose reduction: Expect approximately 33 mg/dL reduction per 10 units of subcutaneous insulin 7
- Hypoglycemia risk: 7.4% incidence of blood glucose <70 mg/dL with protocolized subcutaneous insulin 1
- ED length of stay: Subcutaneous insulin does not prolong ED stay (5.4 hours intervention vs 4.9 hours usual care) 2
For Admitted Patients
If the patient requires admission, initiate basal insulin (detemir or glargine) in the ED before transfer to achieve better inpatient glycemic control (patient-day weighted mean glucose 163 mg/dL vs 202 mg/dL with usual care) 2. This approach also reduces hospital length of stay (3.8 vs 5.3 days) 1.
Fluid Management
Intravenous fluids provide modest glucose reduction (27 mg/dL per liter) but significantly increase ED length of stay by 45 minutes per liter 7. Reserve IV fluids for patients with volume depletion or dehydration, not as primary glucose-lowering therapy.